<DOC>
	<DOCNO>NCT00740129</DOCNO>
	<brief_summary>The purpose study demonstrate patient Paget 's disease bone respond zoledronic acid treatment participant core registration study CZOL446K2304 CZOL446K2305 later experience relapse successfully treat 5mg infusion zoledronic acid .</brief_summary>
	<brief_title>Re-treatment Patients With Paget 's Disease Using Zoledronic Acid</brief_title>
	<detailed_description>Uncontrolled study</detailed_description>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Osteitis Deformans</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Written Informed Consent Patients Paget 's disease randomize zoledronic acid arm CZOL446K2304 CZOL446K2305 core study responders 6 month Confirmed relapse Paget 's disease bone ( i.e . SAP ULN , bone scan , worsen clinical symptom ) A patient previously treat zoledronic acid relapse retreated antiresorptive bisphosphonate calcitonin therapy within last 12 month Bisphosphonate Hypersensitivity Patients suspected/proven metastasis retreatment Calculated creatinine clearance &lt; 35 mL/min screen Serum calcium level &lt; 2.07 mmol/L screen Active primary hyperparathyroidism , hyperparathyroidism , hypoparathyroidism hypothyroidism Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Paget 's Disease</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Reclast®/Aclasta®</keyword>
	<keyword>infusion</keyword>
	<keyword>re-treatment</keyword>
	<keyword>re-lapse</keyword>
</DOC>